20n Bio (pr. "twenty-n bio") is a VC-backed start-up dedicated to designing and screening cyclic peptides for therapeutics. Launched in 2021 and located in Malvern PA, 20n Bio's mission is addressing unmet medical needs by leveraging high-throughput screening and computing to develop peptide drugs with desired biophysical, functional, and pharmacological properties. 

We are looking for enthusiastic scientists to join us to fulfill our mission.

COMPANY NEWS

Jan 31, 2024: 20n Bio Appoints Linghang Zhuang, Ph.D., as President, to lead the discovery of cyclic peptide drugs.